Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits